Sanofi (SNY) Asset Utilization Ratio (2018 - 2026)
Sanofi's (SNY) quarterly Asset Utilization Ratio came in at 0.36 in Q2 2026, up 19.33% year-over-year from 0.3 in Q2 2025, and up 3.38% quarter-over-quarter from 0.35 in Q1 2026.
Powered by 
Analysis
Sanofi (SNY) Asset Utilization Ratio (2018 - 2026) Analysis & Trends
Sanofi has disclosed Asset Utilization Ratio across 3 years of filings, most recently posting 0.36 for Q2 2026.
- In Q2 2026, Asset Utilization Ratio rose 19.33% year-over-year to 0.36; the TTM figure through Jun 2026 stood at 0.36 (up 19.33% YoY), while the FY2024 annual figure was 0.32, up 4.75% from the prior year.
- Asset Utilization Ratio came in at 0.36 for Q2 2026 at Sanofi, up from 0.35 in the prior quarter.
- In the past five years, Asset Utilization Ratio ranged from a high of 0.45 in Q3 2025 to a low of 0.29 in Q1 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 641.14 Bn | 620.38 Bn | 17.26 Bn | 0.49 |
| 2 | AbbVie | 451.04 Bn | 444.47 Bn | 12.70 Bn | 0.47 |
| 3 | Merck | 357.43 Bn | 350.29 Bn | 12.21 Bn | 0.52 |
| 4 | Novartis Ag | 266.73 Bn | 259.04 Bn | 11.24 Bn | 0.57 |
| 5 | Pfizer | 157.52 Bn | 145.82 Bn | 10.94 Bn | 0.31 |
| 6 | Sanofi | 52.14 Bn | 44.76 Bn | 10.79 Bn | 0.36 |
| 7 | Revolution Medicines | 42.88 Bn | 42.88 Bn | - | - |
| 8 | Incyte | 24.70 Bn | 20.16 Bn | 1.57 Bn | 0.77 |
| 9 | United Therapeutics | 21.47 Bn | 18.80 Bn | 683.80 Mn | 0.45 |
| 10 | Neurocrine Biosciences | 15.82 Bn | 15.43 Bn | 935.80 Mn | 0.66 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 0.36 |
| Mar 31, 2026 | 0.35 |
| Dec 31, 2025 | 0.33 |
| Sep 30, 2025 | 0.45 |
| Jun 30, 2025 | 0.30 |
| Mar 31, 2025 | 0.29 |
| Dec 31, 2018 | 0.92 |
| Sep 30, 2018 | 0.90 |
| Jun 30, 2018 | 0.45 |
| Mar 31, 2018 | 0.48 |